Treatment of chronic MRSA infections using a novel aqueous extract of allicin (AB1000)
Abstract number: 1134_03_351
Cutler R.R., Josling P.D., Bennett N.J.
Allicin is recognised as the main bioactive agent from Allium sativum or garlic. This compound is highly active but generally unstable. Using a cold aqueous extraction method, we have obtained a novel extract of allicin (AB1000) that we have reported is stable and highly active in vitro against methicillin resistant Staphylococcus aureus (MRSA).
Due to national publicity of AB1000, patients with long standing unresolved MRSA infections requested this agent for treatment. MRSA is commonly related to delayed closure for many chronic and acute wounds. This is associated with high levels of bacteria in tissues but they can also through toxin secretion. These toxins can cause local necrosis and disrupt the delicate balance of critical mediators such as cytokines and proteases necessary for healing progression.
We present initial findings from three patients who have completed a course of treatment. These courses consisted of capsules (450 mg, 3 per day); spraying liquid AB1000 (1000 mg ml-1) onto the affected areas once per day and applying AB1000 Cream (500 mg ml-1) to the infected area once daily. Patients were screened, nasal and wound for MRSA prior and during treatment. All patients were nose and wound swab MRSA positive prior to treatment. All were over 60 years of age and had either major surgery or long term skin infections leading to the formation of ulcers infected by MRSA. Two of the MRSA infections were community acquired and one hospital acquired. The strains isolated from each patient were tested in vitro against AB1000 and all were susceptible.
Patients reported an improvement in their condition after 2 and 6 weeks treatment and the infections resolved in 34 months. Although the timescales required for treatment may be longer than those normally required using antibiotics, the initial relief from weeping ulcers and pain was much quicker. It should be noted these the patients had been receiving unsuccessful treatment with antibiotics for months or years prior to treatment with AB1000. A possible reason for the initial relief from symptoms could relate to the reported activity of garlic extracts to neutralise bacterial exoenzymes in vitro. This could account for the findings that patients got relief from their symptoms before the MRSA were fully removed from the lesion site.
|Session name:||XXIst ISTH Congress|
|Back to top|